The global acute myeloid leukemia (AML) therapeutics market is set to expand significantly, with forecasts indicating it will grow from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report from Fact.MR. The market is expected to register a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036, creating an absolute dollar opportunity of approximately USD 5.9 billion, nearly 2.4 times its current value. This growth is largely attributed to the increasing adoption of precision oncology, targeted therapies, and personalized medicine approaches that are transforming the management of acute myeloid leukemia worldwide.
Healthcare providers are increasingly incorporating molecular diagnostics and mutation-based treatment selection into routine practice. This shift is moving AML therapeutics away from traditional chemotherapy-focused regimens toward highly individualized treatment pathways designed to improve patient outcomes and reduce disease recurrence. Targeted therapies are expected to account for 36% of market share in 2026, making them the leading drug class. The availability of mutation-specific drugs, such as those targeting FLT3 and NPM1, is expanding treatment options for patients with genetically defined AML subtypes, offering enhanced efficacy and improved tolerability compared to conventional approaches.
By disease type, newly diagnosed AML is projected to hold 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Hospitals remain the leading end-user segment, accounting for 55% of market demand due to the intensive inpatient management required for AML treatment, including blood transfusion support, chemotherapy administration, and continuous monitoring. Similarly, hospital pharmacies maintain a dominant position with 49% market share, driven by the complexity of AML therapies and the need for specialized handling and administration protocols.
A key growth driver is the increasing availability of therapies for relapsed and refractory AML patients. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the treatment landscape, offering new hope for difficult-to-treat forms of AML. According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations."
Regionally, South Asia and East Asia are emerging as high-growth areas due to expanding cancer care infrastructure and increasing access to molecular diagnostics. North America continues to lead market revenues, while Western Europe remains an important market. Among key countries, India is projected to grow at an 11.8% CAGR, China at 10.9%, the United States at 8.7%, Germany at 7.9%, and Japan at 7.4%. The competitive landscape includes major pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc., which are investing in precision medicine, molecular diagnostics partnerships, and clinical trials.
The full report, which includes detailed forecasts, pricing trends, and strategic recommendations, can be accessed at Fact.MR's AML Therapeutics Market Report. A sample report is also available at this link. The future outlook remains positive as innovation continues to reshape the global hematology treatment landscape, despite challenges related to treatment costs, toxicity management, and reimbursement constraints.
